Welcome to the new Gustave Roussy website
A new website designed to offer you a simpler, clearer, and more intuitive experience. Patients, caregivers, healthcare professionals, and donors: find information, news, and services more easily.
OASIS: Better Predicting the Response to and Resistance Against Antibody Conjugates
European research program coordinated by Gustave Roussy
Led by Dr. Barbara Pistilli and coordinated by Gustave Roussy, OASIS is studying antibody-drug conjugates (ADCs). The program aims to better understand why some patients respond to these treatments while others develop resistance or experience significant toxicity. Ultimately, it should enable the development of companion diagnostic tests and a digital decision-support tool to guide each patient toward the ADC best suited to their clinical profile and tumor biology.
-
9.9 million euros
European funding
-
5 years
research
-
12
partners
-
3 countries
for the prospective cohort
What are antibody conjugates?
An antibody-drug conjugate (ADC) combines an antibody with a cytotoxic drug. The antibody recognizes a target present on the surface of certain tumor cells and delivers the drug to that site. After the complex is internalized, the cytotoxic molecule is released into the cell to destroy it.
This approach aims to further concentrate the drug’s action on cells that express the target. However, it does not eliminate the risk of adverse effects. Its efficacy may also be limited by insufficient or heterogeneous expression of the target, poor penetration into the tumor, or the development of resistance mechanisms.
Why the OASIS program?
Antibody-drug conjugates have expanded therapeutic options for several cancers. However, their benefits vary among patients and may be compromised by resistance or toxicities, particularly pulmonary, neurological, or cutaneous ones. OASIS aims to identify the clinical, biological, and radiological characteristics associated with response and tolerability in order to better guide treatment selection.
The five objectives of the program
|
1. Understanding resistance Identify the mechanisms that reduce or prevent the action of ADCs. |
2. Study toxicities Investigate the factors associated with the serious adverse effects observed with these treatments. |
|
3. Identify biomarkers Detect characteristics that can provide information on response, resistance, or the risk of toxicity. |
4. Develop decision-support tools Design companion diagnostic tests and the OASIS score to help select the most appropriate ADC. |
|
5. Design a new ADC Develop and then evaluate, as part of the program, an ADC designed to overcome certain resistance mechanisms. |
Two cohorts for studying patients
OASIS relies on two complementary cohorts. The first is retrospective and compiles data from French patients who have already been treated. The second is prospective, as part of a multicenter clinical trial conducted in France, Belgium, and Greece. This approach will enable the study of factors associated with response, resistance, and toxicity in various clinical settings.
A range of complementary tests
Patients participating in the program will have access to various research tests. Cross-referencing their results should help build a more comprehensive understanding of the tumor, treatment distribution, and the body’s response.
|
ImmunoPET This nuclear medicine technique uses antibodies labeled with a positron emitter to map the ADC target within the tumor and healthy tissues. |
Digital pathology and artificial intelligence Digital analysis of tumor tissues will help characterize the tumor and the distribution of the ADC target within the sample. |
|
Liquid biopsy A blood draw allows for the analysis of circulating tumor cells and certain proteins present in the serum, among other things. |
Molecular analyses of the tumor Proteomic, genomic, and transcriptomic analyses examine the proteins, DNA, and RNA of the tumor and its microenvironment. |
|
Tumor organoids These three-dimensional models are developed from patients’ tumor cells. They will be used to study resistance mechanisms and to test combination therapies in the laboratory. |
Understanding Biomarkers
A biomarker is a measurable characteristic, such as one found in blood, a medical image, or a tumor sample. In OASIS, the biomarkers under study must still be validated before they can potentially be used to predict the efficacy of an ADC or the risk of toxicity.
A Closer Look at the OASIS Score
One of the program’s goals is to develop an artificial intelligence model that combines clinical, biological, and radiological data. Called the OASIS score, this research tool is designed to estimate, for each patient, the probability of response to various ADCs and the risk of associated toxicities.
The goal is to provide physicians with additional information to guide treatment decisions. Before it is used in clinical practice, the performance, robustness, and utility of this score must be evaluated and validated.
Video Explanations
A European, multidisciplinary consortium
OASIS brings together twelve partners from academia, hospitals, the technology sector, industry, and nonprofit organizations. The consortium combines expertise in oncology, imaging, pathology, molecular biology, modeling, drug development, and patient advocacy.
| Gustave Roussy (France) | Inserm (France) |
| Unicancer (France) | French Atomic Energy and Alternative Energies Commission (France) |
| Olink Proteomics AB (Sweden) | Elikya Therapeutics (France) |
| National and Kapodistrian University of Athens (Greece) | Jules Bordet Institute (Belgium) |
| Orakl Oncology (France) | CentraleSupélec (France) |
| Cancer Patients Europe (Belgium) | University of Crete (Greece) |
A project supported by the European Union
OASIS has received a grant of 9.9 million euros from the European Commission for a period of 60 months, as part of the Horizon Europe program. The grant agreement number is 101156771.
Funding Acknowledgment
Funded by the European Union. However, the views and opinions expressed are those of the authors alone and do not necessarily reflect those of the European Union or the European Executive Agency for Health and Digital (HaDEA). Neither the European Union nor the granting authority shall be held liable for this.
Frequently Asked Questions
No. This is a tool that was developed and evaluated as part of the research program. No. This is a tool that was developed and evaluated as part of the research program.
No. They are conducted in accordance with the protocol and eligibility criteria for the OASIS program. No. They are conducted in accordance with the protocol and eligibility criteria for the OASIS program.
An ADC combines an antibody that targets a characteristic of tumor cells with a cytotoxic molecule. It is therefore a treatment that combines targeting with the delivery of a cytotoxic drug.An ADC combines an antibody that targets a characteristic of tumor cells with a cytotoxic molecule. It is therefore a treatment that combines targeted delivery with the delivery of a cytotoxic drug.
No. These are laboratory models used to study the tumor and test hypotheses. They are not a substitute for clinical trials or medical decision-making. No. These are laboratory models used to study the tumor and test hypotheses. They are not a substitute for clinical trials or medical decision-making.